Prof Lemmens underscores large unmet medical need in intracerebral hemorrhage “Very encouraging” data from Phase 2a trial with lead asset BIOX-101 ; Bioxodes is preparing for ...
In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI ® in ...
In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI ® in ...
COPENHAGEN, Denmark, November 14, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2025 and business progress for the third quarter of ...
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are comprised of equity investments, including from Cochlear, Resmed and Nyxoah’s ...
In August 2024, LEQEMBI was approved for the treatment of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4)* ...
Bagsværd, Denmark, 13 November 2025 – Today, it was announced that Mikael Dolsten will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025, as ...
Copenhagen, Denmark, 13 November 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), announces that the private placement of 40,438,426 new shares has been completed. The ...
SAB BIO reported net income of $45.4 million and a net loss of $10.3 million for the three months ended September 30, 2025 and 2024, respectively, and net income of $30.1 million and a net loss of $22 ...
The Phase 2b part of the RESOLVE trial, a randomized placebo-controlled study of EP-104GI, is currently recruiting with the first clinical dose of 120mg (20 x 6mg). The top-line data from the Phase 2b ...
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
Additionally, Appili believes that ATI-1801 may be eligible for a Priority Review Voucher (“PRV”), when approved by the FDA. PRVs have recently been monetized for amounts in excess of US$150 million.
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and nine months ended September 30, 2025 on Thursday, November 20, 2025 after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback